Boutique Biotech Boutique insights into the biotech stock market from a University of Chicago faculty member
Boutique Biotech • 2 likes • 29 Sep 22 Medicenna in the spotlight (part X) Deep-dive on new data update
Boutique Biotech • 1 likes • 23 Nov 22 Medicenna & Jounce Therapeutics in the spotlight New updates from $MDNA and $JNCE
Boutique Biotech • 1 likes • 31 Oct 22 Medicenna in the spotlight (part XI) Re-evaluating the IL-2 thesis relative to recent Sanofi news
Boutique Biotech • 0 likes • 11 Jul 22 Milestone Pharmaceuticals and Astria Therapeutics in the spotlight Deep-dive fundamental and technical analysis of $MIST and $ATXS
Boutique Biotech • 0 likes • 11 Mar 23 Silicon Valley Bank in the spotlight Assessing impact on list of biotech companies with deposit exposure
Boutique Biotech • 0 likes • 07 Jun 22 ASCO meeting recap -- prospects for a reversal? Analyzing Pfizer, GSK, BMS, Janssen, AstraZeneca, Mirati, Amgen, and others...
Boutique Biotech • 0 likes • 17 Oct 22 Milestone Pharmaceuticals in the spotlight (part IV) Phase 3 results and stock momentum heading into 2023
Boutique Biotech • 0 likes • 10 Aug 22 Medicenna in the spotlight (part IX) Aftermath of financing, implications, and long-term outlook
Boutique Biotech • 0 likes • 26 Jun 22 Boutique Biotech portfolio in the spotlight Mid-year updates on $AFMD, $NMTR, $FSTX, and $MDNA
Boutique Biotech • 0 likes • 21 Mar 23 Karuna Therapeutics in the spotlight Fundamental & technical deep-dive on science and stock
Boutique Biotech • 0 likes • 05 Jul 22 9 Meters, Jounce, and Merck updates Proof-of-concept data and expectations on anti-ILT4/anti-ILT3 programs and more!
Boutique Biotech • 0 likes • 11 Feb 23 aTyr Pharma in the spotlight Recent financing and future outlook
Boutique Biotech • 0 likes • 31 Mar 23 Day One Biopharmaceuticals in the spotlight (part II) Impact of Novartis’ Approval on $DAWN and Confusion Around Endpoint Change
Boutique Biotech • 0 likes • 08 Aug 22 Milestone Pharmaceuticals in the spotlight (part II) Starting MIST position and updates on JNCE/ATSX, all which have catalysts coming up
Boutique Biotech • 0 likes • 22 May 23 Pfizer in the spotlight Oral obesity treatments & competitive landscape assessment in GLP-1 market
Boutique Biotech • 0 likes • 12 Apr 23 $XBI in the spotlight and trends to watch out for When will markets rebound? And other questions...
Boutique Biotech • 0 likes • 20 Sep 22 Astria Therapeutics in the spotlight (part III) >150% gains since last month but Boutique Biotech still holding position
Boutique Biotech • 0 likes • 19 Sep 22 Milestone Pharmaceuticals in the spotlight (part III) Selling MIST position to lock in 30% gains
Boutique Biotech • 0 likes • 05 Nov 22 Affimed update ASH22 Preliminary Data and Artiva the NK Source Commercial Partner
Boutique Biotech • 0 likes • 31 Dec 22 Jounce, F-star, and Astria Therapeutics End-of-year summary and predictions into 2023
Boutique Biotech • 0 likes • 27 Dec 22 Affimed in the spotlight (part II, ASH 2022 update) Key opinion leader insights on latest AFMD data
Boutique Biotech • 0 likes • 12 Dec 22 Affimed in the spotlight AFM13 data announcement at ASH conference
Boutique Biotech • 0 likes • 10 Jan 23 Affimed in the spotlight (part III) A look at biotech market, NK cell sentiment, and AFMD update
Boutique Biotech • 0 likes • 20 Jan 23 Boutique draft picks for 2023-24 New biotech/pharma names to watch this year
Boutique Biotech • 0 likes • 06 Feb 23 Addex Therapeutics in the spotlight Diminished enthusiasm in $ADXN
Boutique Biotech • 0 likes • 23 Feb 23 Affimed, Medicenna, and Karuna Therapeutics in the spotlight Sliding scales on $AFMD, $MDNA, and $KRTX
Boutique Biotech • 0 likes • 02 Mar 23 Day One Biopharmaceuticals in the spotlight Scientific deep-dive on data and investment potential
Boutique Biotech • 0 likes • 13 Mar 23 Silicon Valley Bank in the spotlight (part II) Plus analysis of Monday's latest biotech M&A news (Seagen & Provention Bio)
Boutique Biotech • 0 likes • 24 Mar 23 Affimed in the spotlight Will the AFM13+NK trial be registrational? When will $AFMD report AFM24 + PD-L1 and AFM24+autologous NK data?
Boutique Biotech • 0 likes • 19 Apr 23 Antibody-drug conjugate (ADC) technology back in cancer biotech spotlight ADC trends, developments, and next hot targets: discover the upcoming ADC catalysts and public companies to benefit most in next 9 months
Boutique Biotech • 0 likes • 26 Apr 23 Sign of the times... Rising M&A volume in the biopharma sector
Boutique Biotech • 0 likes • 26 Apr 23 Biotech Basics: How to Spot When Financing Is Coming Educational content for biotech investing
Boutique Biotech • 0 likes • 01 May 23 Biotech Basics: Often Misunderstood Details of Biotech Financings Educational content for biotech investing
Boutique Biotech • 0 likes • 03 May 23 $VKTX, $GPCR, $RYTM, $ACIU, $VYGR, $KRTX, $ITCI, $PRQR, $ARWR, $ALNY, and more... Bullish trends & names to watch for in the biotech market
Boutique Biotech • 0 likes • 08 May 23 Eli Lilly in the spotlight Assessing latest data in Alzheimer's disease
Boutique Biotech • 0 likes • 17 May 23 Amgen & Horizon Therapeutics in the spotlight FTC Pauses Biotech Rally, But Show Must Go On...
Boutique Biotech • 0 likes • 17 May 23 Biotech Basics: Interpreting Data Readouts Educational content for biotech investing
Boutique Biotech • 0 likes • 05 Aug 22 Astria Therapeutics in the spotlight (part II) Analyzing $ATXS data and upside relative to F-Star Therapeutics, while comparing to Takeda and BioCryst options